Polaryx Therapeutics, Inc. Common Stock
Stock Chart, Company Information, and Scan Results
Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.
Polaryx Therapeutics, Inc. Common Stock Company Information, Fundamentals, and Technical Indicators
Polaryx Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of disease-modifying therapies for rare and pediatric lysosomal storage disorders in the United States. Its pipeline includes PLX-100, a preclinical stage orally administrable combination therapy; PLX-200, a repurposed oral small molecule for the treatment of LSDs; PLX-300, a preclinical stage orally administrable combination therapy; and PLX-400, a preclinical stage novel gene therapy candidate. The company was founded in 2014 and is based in Paramus, New Jersey.
Polaryx Therapeutics, Inc. Common Stock In Our Stock Scanner
As of Aug 19, 2026
Join Our Free Email List
Get emails from us about ways to potentially make money in the stock market.